Flow cytometric analysis and bone marrow examination confirmed AML-MRC, characterized by 42% blasts expressing CD13, human leukocyte antigen (HLA)-DR, myeloperoxidase (MPO), megakaryocytic dysplasia, and left shift in maturation. This evidence concerns the gene MPO and acute myeloid leukemia.